Astera Labs (ALAB) reported strong Q3 2025 results. Revenue rose to $230.6 million, up 104% year over year, as higher unit shipments and a richer mix of modules and Scorpio products drove growth. Gross margin was 76.2% versus 77.7% a year ago, reflecting product mix. Operating income reached $55.4 million, and an income tax benefit contributed to net income of $91.1 million (diluted EPS $0.50), compared with a loss last year.
For the first nine months, revenue was $581.9 million (up 128%) with net income of $174.2 million. Cash and cash equivalents were $140.4 million and marketable securities were $994.0 million as of September 30, 2025. Q3 revenue was led by Singapore ($95.6 million), China ($77.4 million), and Taiwan ($37.7 million). Non-GAAP results highlighted operating margin of 41.7% and net income of $88.2 million. Shares outstanding were 168,903,616 as of October 31, 2025. Management noted higher headcount and R&D investments, while the One Big Beautiful Bill Act drove a tax benefit that reduced current U.S. cash taxes.
Astera Labs, Inc. filed a current report to let investors know it has released a press release with its financial results for the quarter ended September 30, 2025. The company furnished this press release, dated November 4, 2025, as Exhibit 99.1, meaning it is provided for information but is not treated as formally filed under certain liability provisions of the securities laws. The report is signed on behalf of Astera Labs by Chief Financial Officer Michael Tate.
Astera Labs, Inc. (ALAB) reported that it entered into a definitive agreement to acquire aiXscale Photonics GmbH. The company announced the agreement on October 22, 2025 and furnished a related press release as Exhibit 99.1.
The update was provided under Item 8.01 (Other Events) of a Form 8-K. Astera Labs’ common stock trades on the Nasdaq Global Select Market.
Philip Mazzara, General Counsel and Secretary of Astera Labs, Inc. (ALAB), reported automatic sales of 10,000 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan adopted on May 29, 2025. The Form 4 lists nine sell transactions executed the same day at weighted average prices for each block, with reported price ranges across the trades from $186.67 up to $195.48. Following the reported sales, the filing shows the reporting person beneficially owns 151,573 shares.
The Form 4 is signed by Mr. Mazzara on 10/03/2025 and contains explanatory footnotes stating the per-block prices are weighted averages and that detailed per-trade price breakdowns are available on request. No derivative securities are reported on this Form 4.
Astera Labs director Manuel Alba-Marquez reported multiple sales of Company common stock on 09/02/2025 executed under a Rule 10b5-1 trading plan adopted May 29, 2025. The Form 4 lists a sequence of discrete dispositions at weighted-average prices in rising price bands (roughly $167.59–$180.53 per share) and states the resulting beneficial ownership figures held indirectly by the Alba Trust and Casa Alameda 2007, LLC. Following the reported transactions, the filing shows the Alba Trust's indirect holdings at 1,724,498 shares and Casa Alameda 2007, LLC's indirect holdings at 385,863 shares; the reporting person also notes 5,000 shares owned by a spouse.
Astera Labs insider transfer and holdings update. Director and President/COO Gajendra Sanjay reported transactions on 09/02/2025 moving 480,668 shares of common stock. The filing shows a corresponding reduction in directly held shares to 1,690,209 and an increase in indirectly beneficially owned shares to 6,006,213 held by three estate planning trusts. The Form 4 states the 480,668-share transfers to Trust 1 were for $0 and that Trusts 1–3 each hold 695,000 shares as described; the reporting person disclaims beneficial ownership of trust-held shares except for any pecuniary interest. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Philip Mazzara, General Counsel and Secretary of Astera Labs, Inc. (ALAB), sold 10,000 shares of company common stock on 08/28/2025 under a pre-established Rule 10b5-1 trading plan adopted May 29, 2025. The sales occurred in multiple transactions at prices ranging approximately from $182.55 to $190.91 per share; weighted-average prices are reported for several tranches. Following these dispositions, the reporting person’s beneficial ownership is reported as 161,573 shares, held directly. The Form 4 discloses that the transactions executed automatically under the trading plan.
Astera Labs, Inc. (ALAB) filing a Form 144 notifies a proposed sale of 33,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,012,600.00. The shares were acquired 11/30/2018 in a private acquisition from the issuer and paid in cash. The filing lists multiple prior 10b5-1 sales by related trusts and entities between 06/20/2025 and 07/21/2025, including individual sales of 51,000, 58,000, 29,000 and others. The signer represents no undisclosed material adverse information and cites a Rule 10b5-1 trading plan context where applicable.
Form 144 notice for Astera Labs, Inc. (ALAB) reporting a proposed sale of 150,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ. The filing lists an aggregate market value of $27,330,000 for the block and reports total shares outstanding of 166,219,140. The shares were acquired 03/21/2018 in a private acquisition from the issuer and paid in cash. The filing also discloses multiple Rule 10b5-1 sales by related trusts and entities in the past three months totaling 237,100 shares for gross proceeds of $22,136,140.67. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Astera Labs (ALAB) submitted a Form 144 notifying the market of a proposed sale of 170,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $30,974,000 and an approximate sale date of 09/02/2025. The shares were acquired in a private issuance from the issuer on 03/21/2018 and were paid for in cash. The filing shows total shares outstanding of 166,219,140, and discloses multiple recent Rule 10b5-1 sales by related trusts between 06/20/2025 and 07/21/2025, with individual gross proceeds listed for each transaction. The signer certifies no undisclosed material adverse information and references reliance on planned trading instructions where applicable.